Tag: Dr George D Yancopoulos

Dupixent (dupilumab)

Dupixent® Phase 3 Trial Shows Positive Results in Children Ages 1-11...

Majority of patients achieved histological disease remission in 16 weeks.
Dupixent

FDA Approves Dupixent® as First Biologic for Treatment of Children Aged...

Three-quarters of patients receiving Dupixent achieved at least a 75% improvement in overall disease, with an average improvement of approximately 80%.
dupilumab

FDA Approves Dupixent® (dupilumab) for Moderate-to-severe Atopic Dermatitis in Adolescents

Therapy targets the IL-4/IL-13 pathway, a key driver of the allergic or type 2 inflammation that underlies atopic dermatitis.
AR101+dupilumab

Aimmune Therapeutics Announces Initiation of Phase 2 Study of AR101 With...

Trial Will Build on the Positive, Pivotal Phase 3 PALISADE Trial of AR101.
dupilumab

Study: Dupilumab Showed Positive Phase 3 Results in Adolescents with Inadequately...

"[dupilumab] blocks the IL-4/IL-13 pathway, which is emerging as a central driver of Type 2 allergic inflammation."